US EditionPublished • loading... • Updated
More CF patients eligible for CFTR modulators after FDA expansion
Summary by Cystic Fibrosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
More CF patients eligible for CFTR modulators after FDA expansion
The U.S. Food and Drug Administration (FDA) has expanded the approvals of two Vertex Pharmaceuticals therapies to include additional mutations that cause cystic fibrosis (CF), allowing more people with the condition to become eligible for treatment. The decision concerns Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) and Trikafta (elexacaftor/tezacaftor/ivacaftor). These are CFTR modulators that help improve the function of the CFTR protein, wh…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
